Home › Linfoma di Burkitt › Georgia › Atlanta
Studi clinici su Linfoma di Burkitt a Atlanta, GA
12 studi su Linfoma di Burkitt cercano partecipanti presso sedi a Atlanta e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
In reclutamentoFase 2
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
In reclutamentoFase 3
- Emory University Hospital/Winship Cancer Institute, Atlanta
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
In reclutamentoStudio osservazionale
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
In reclutamentoFase 2
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
In reclutamentoFase 2
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
In reclutamentoFase 1
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
In reclutamentoFase 2
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
In reclutamentoFase 3
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
In reclutamentoFase 2
- Children's Healthcare of Atlanta at Egleston, Atlanta
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
In reclutamentoFase 1/2
- Research Site, Atlanta
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
In reclutamentoFase 1
- Winship Cancer Institute, Emory University, Atlanta
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
In reclutamentoFase 2
- Children's Healthcare of Atlanta, Atlanta
Studi su Linfoma di Burkitt in altre città
- Houston, TX21 studi
- Milwaukee, WI16 studi
- Philadelphia, PA16 studi
- New York City, NY14 studi
- Chicago, IL14 studi
- Cincinnati, OH12 studi
- Seattle, WA11 studi
- Durham, NC10 studi
- Boston, MA10 studi
- Los Angeles, CA10 studi
- Aurora, CO10 studi
- Kansas City, MO10 studi
Altri studi a Atlanta
- Cancro (tutti i tipi)49 studi
- Cancro del polmone non a piccole cellule47 studi
- Cancro al seno41 studi
- Mieloma multiplo41 studi
- Cancro alla prostata33 studi
- Leucemia mieloide acuta30 studi
- Cancro ovarico29 studi
- Cancro ai polmoni29 studi
- Cancro colorettale29 studi
- Cancro metastatico28 studi
- Insufficienza cardiaca25 studi
- Disturbo depressivo maggiore25 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.